Found 1971 with Last Name = 'michels' and Initial = 't' TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 0.0700nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 0.832nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.05nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.08nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.11nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.11nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.32nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.36nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.40nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
Affinity DataIC50: <1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: <1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: <1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: <1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: <1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: <1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: <1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: <1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
3D Structure (crystal)Affinity DataIC50: 1.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
TargetEukaryotic initiation factor 4A-I(Homo sapiens (Human))
Inception Therapeutics
Curated by ChEMBL
Inception Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif r...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.52nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.57nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.57nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
Affinity DataIC50: 1.59nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 1.75nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.12nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.25nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.26nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic initiation factor 4A-I(Homo sapiens (Human))
Inception Therapeutics
Curated by ChEMBL
Inception Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.30nMAssay Description:Inhibition of eIF4A (unknown origin) assessed as inhibition of translation of RNA featuring highly structured 5'-UTR of c-MycMore data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.33nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.37nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.44nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.44nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.45nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.79nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.87nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.87nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.92nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
Affinity DataIC50: 2.96nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 2.98nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 3.02nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 3.12nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 3.12nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 3.12nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 3.15nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 4E-binding protein 1(Homo sapiens (Human))
Effector Therapeutics
US Patent
Effector Therapeutics
US Patent
Affinity DataIC50: 3.18nMAssay Description:eIF4E protein was pre-incubated with EDA-m7GDP-ATTO-550 in FPB at 2xconcentrations for 5 minutes prior to the addition of compounds. Compounds (100x)...More data for this Ligand-Target Pair
